Cargando…
Inhibition of Exosome Release Sensitizes U937 Cells to PEGylated Liposomal Doxorubicin
AIMS: Acute myeloblastic leukemia (AML) is the most common type of acute leukemia in adults. Despite numerous treatment strategies including chemotherapy and radiotherapy, a large number of patients do not respond to treatment and experience relapse. The main problem of these patients is the develop...
Autores principales: | Hekmatirad, Shirin, Moloudizargari, Milad, Moghadamnia, Ali Akbar, Kazemi, Sohrab, Mohammadnia-Afrouzi, Mousa, Baeeri, Maryam, Moradkhani, Fatemeh, Asghari, Mohammad Hossein |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212994/ https://www.ncbi.nlm.nih.gov/pubmed/34149737 http://dx.doi.org/10.3389/fimmu.2021.692654 |
Ejemplares similares
-
Pegylated liposomal doxorubicin in ovarian cancer
por: Green, Andrew E, et al.
Publicado: (2006) -
Pegylated liposomal doxorubicin in ovarian cancer
por: Strother, Robert, et al.
Publicado: (2009) -
Pegylated liposomal doxorubicin for myeloid neoplasms
por: Zhang, Cheng, et al.
Publicado: (2019) -
Pegylated liposomal doxorubicin in the management of ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2010) -
A tale of the two PEGylated liposomal doxorubicins
por: Chou, Hunghsueh, et al.
Publicado: (2015)